Top Key-Players To Deepen The Growth Curve For Injectable Nanomedicines Market

Posted by Merin John on April 29th, 2021

The growth of the injectable nanomedicines market is attributed to the growing use of liposomal drugs and increase in treatment seeking population across the globe.

According to a latest research by the company, the global liposomes market is expected to account for revenues over US$ 300 Mn in terms of value by 2026 end. Injectable nanomedicines market is expected to witness significant growth with CAGR pegged at 8.1% through 2026. Manufacturers of injectable nanomedicines are targeting chronic diseases and cancers.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25999

Company Profiles

Merck & Co., Inc.

Lupin

Pacira Pharmaceuticals Inc.

Celgene Pharmaceutical Co. Ltd.

Amgen, Inc.

Janssen Biotech Inc. (Sub. Johnson & Johnson Services, Inc.)

Pfizer Inc.

Hoffmann-La Roche Ltd.

Teva Pharmaceutical Industries Ltd.

Bausch & Lomb Incorporated.

Revenues from North America injectable nanomedicines market is expected to expand at significant CAGR and it is estimated to remain as dominant regional market for injectable nanomedicines due to large presence of hospitals and advanced healthcare facilities.

Europe is also expected to be one of the leading regional markets for injectable nanomedicines as most of the major academic research institutes and R&D institutes for specialized drugs are located in the region. An ageing population and increasing prevalence of chronic illnesses is estimated to lead to rising demand for injectable nanomedicines.

Injectable nanomedicines are considered as an emerging field with many companies spending on R&D to explore this field in greater depth.

There are both small and established market players investing in injectable nanomedicines. Majority of injectable nanomedicines were produced by small pharmaceutical companies which were later acquired by established market players.

Small pharmaceutical companies are exploring nanotechnology to develop advanced drugs and technologies.  For instance, Pfizer collaborated with BIND Therapeutics Inc for the development of nanoparticles, called Accurins.